Professor Edna Mozes
Professor of Immunology E-mail: edna.mozes@weizmann.ac.il Phone: +972-8-934-3646 Fax: +972-8-934-4173 Location: Wolfson Bldg., Room 526 |
Publications (last 3 years)
- D. Luger, M. Dayan, H. Zinger, J.-P. Liu and E. Mozes. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 24: 579-590 (2004).
- N. Mauermann, Z. Sthoeger, H. Zinger and E. Mozes. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin. Exp. Immunol. 137: 513-520 (2004).
- M. Dayan, Z. Sthoeger, A. Neiman, J. Abarbanel, M. Sela and E. Mozes. Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. Human Immunol. 65: 571-577 (2004).
- M. Sela and E. Mozes. Therapeutic vaccines in autoimmunity. Proc. Natl. Acad. Sci. USA 101: 14586-14592 (2004).
- U. Sela, R. Hershkoviz, L. Cahalon, O. Lider and E. Mozes. Down-regulation of stromal cell-derived factor-1a-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF- secretion. J. Immunol. 174: 302-309 (2005).
- U. Sela, N. Mauermann, R. Hershkoviz, H. Zinger, M. Dayan, L. Cahalon, J.-P. Liu, E. Mozes and O. Lider. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF- mediated suppression of LFA-1 and CD44 expression and function. J. Immunol. 175:7255-7263 (2005).
- E. S. Husebye, Z.M. Sthoeger, M. Dayan, H. Zinger, D. Elbirt, M. Levite and E. Mozes. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64: 1210-1213 (2005).
- E. Mozes, J. Lovchik, H. Zinger and D.S. Singer. MHC class I expression regulates susceptibility to spontaneous autoimmune disease in (NZBxNZW)F1 mice. Lupus 14: 308-314 (2005).
- M.J. Rapoport, A. Sharabi, D. Aharoni, O. Bloch, H. Zinger, M. Dayan and E. Mozes. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin. Immunol. 117: 262-270 (2005).
- H. Ben-David, M. Sela and E. Mozes. Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+ CD25+ -regulated events leading to apoptosis. Proc. Natl. Acad. Sci. USA 102: 2028-2033 (2005).
- B.V. Aruna, M. Sela and E. Mozes. Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells. Proc. Natl. Acad. Sci. USA 102: 10285-10290 (2005).
- B.V. Aruna, H. Ben-David, M. Sela and E. Mozes. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis. Immunology 118:413-424 (2006).
- B.V. Aruna, M. Sela and E. Mozes. Down regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+CD25+ regulatory cells. J. Neuroimmunol. 177: 63-75 (2006).
- A. Sharabi, A. Haviv, H. Zinger, M. Dayan and E. Mozes. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: Different effects on cytokines and apoptosis. Clin. Immunol. 119:146-155 (2006).
- E. Voronov, M. Dayan, H. Zinger, L. Gayvoronsky, J.-P. Liu, Y. Iwakura, R.N. Apte and E. Mozes. IL-1-deficient mice are resistant to induction of experimental SLE. Eur. Cytokine Netw. 17: 109-116 (2006).
- E.S. Husebye, E. Bratland, G. Bredholt, M. Fridkin, M. Dayan and E. Mozes. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology 147: 2411-2416 (2006).
- H. Ben-David, B.V. Aruna, R. Seger, M. Sela and E. Mozes. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc. Natl. Acad. Sci. USA 103:18232-18237 (2006).
- Z. Sthoeger, A. Neiman, D. Elbirt, H. Zinger, E. Magen, R. Burstein, S. Eitan, J. Abarbanel and E. Mozes. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: A clinical and serologic study. Am. J. Med. Sci. 331:4-9 (2006).
- U. Sela, M. Dayan, R. Hershkoviz, L. Cahalon, O. Lider and E. Mozes. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur. J. Immunol. 36: 2971-2980 (2006).
- A. Sharabi, H. Zinger, M. Zborowsky, Z.M. Sthoeger and E. Mozes. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-. Proc. Natl. Acad. Sci. USA 103: 8810-8815 (2006).
- H. Ben-David, B.V. Aruna, M. Sela and E. Mozes. A dual altered peptide ligand inhibits myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells. Scandinavian J. Immunol. 65:567-576 (2007).
- A. Elmann, A. Sharabi, M. Dayan, H. Zinger, R. Ophir and E. Mozes. Altered gene expression in mice with lupus treated with Edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 56: 2371-2381 (2007).
- A. Sharabi, H. Azulai, Z.M. Sthoeger and E. Mozes. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophophamide: similarities and differences in the mechanisms of action. Immunology 121: 248-257 (2007).
- A. Sharabi, D. Luger, H. Ben-David, M. Dayan, H. Zinger and E. Mozes. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J. Immunol. 179: 4979-4987 (2007).
- H. Ben-David, A. Sharabi, M. Dayan, M. Sela and E. Mozes. The role of CD8+CD28- regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc. Natl. Acad. Sci. 104: 17459-17464 (2007).